<DOC>
	<DOCNO>NCT02734602</DOCNO>
	<brief_summary>This study design examine SV2A density MDD PTSD correlate synaptic density , determine whether ketamine administration reverse synaptic loss vivo human subject . To knowledge , first human study examine SV2A vivo MDD PTSD use first know drug ( ketamine ) rapidly reverse synaptic loss determine whether ketamine administration could restore structural change associate depression PTSD . After screen process determine eligibility , subject participate MRI , 2-3 PET scan administration ketamine one scan . Cognitive test stress test may also do scan day .</brief_summary>
	<brief_title>Imaging SV2A Mood Disorders</brief_title>
	<detailed_description>The goal study determine whether alteration synaptic vesicle glycoprotein 2A ( SV2A ) , protein express ubiquitously synaptic vesicle , depression anxiety whether ketamine , N-Methyl-D-aspartate ( NMDA ) antagonist , normalize SV2A density time great anti-depressant response . This study conduct examination SV2A associate consequence use neuroreceptor image behavioral technique follow aim . Aim 1 : To compare SV2A availability individual MDD , healthy control individual , individual PTSD use APP311 PET . Hypothesis 1 : This study hypothesize low SV2A density MDD PTSD prefrontal cortex . Aim 2 : To determine whether ketamine administration alters SV2A density HC , MDD , PTSD individual . Hypothesis 2 : This study hypothesize administration ketamine lead significant increase SV2A density subject group ( HC , MDD , PTSD ) , increase correlate antidepressant response individual MDD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>General inclusion criterion : 1 . Subjects 1855 year old , 2 . English speaking , 3 . No DSMIV diagnosis present , besides require . Inclusion criterion depressed subject : 1 . Meet DSMIV diagnostic criterion Major Depressive Disorder , current depressive episode . 2 . Treatment nontreatment seek understand study research purpose . Inclusion criterion healthy control : 1 . No current , history DSMIV diagnosis , 2 . No firstdegree relative history psychotic , mood , anxiety disorder . Inclusion criterion PTSD subject : 1 . Current Post Traumatic Stress Disorder . 1 . History significant medical illness . 2 . Lifetime history neurologic abnormality include significant head trauma , seizure disorder , cerebrovascular neoplastic lesion , neurodegenerative disorder . 3 . Full scale IQ low 70 . 4 . Contraindication MRI scan include claustrophobia presence ferromagnetic object , include orthodontic brace . All participant screen metal object method use routine clinical MRI scanning . 5 . Pregnancy breastfeed . 6 . Alcohol/illicit substance dependence past year meet alcohol/illicit substance abuse within past 6 month . 7 . Current psychosis , active suicidal homicidal ideation . 8 . Positive urine toxicology screen . 9 . Contraindications PET ( e.g. , past current diagnosis cancer , poor venous access placement venous line ) . 10 . History prior radiation exposure research purpose within past year participation study would place FDA limit annual radiation exposure . 11 . Previous anticipated radiation exposure work within one year propose research PET scan precludes study participation . 12 . Blood pressure &gt; 140/80 . 13 . History bleed disorder currently take anticoagulant ( Coumadin , Heparin , Pradaxa , Xarelto ) . 14 . Blood donation within eight week start study . 15 . Current diagnosis MDD PTSD psychotic feature . 16 . First degree relative diagnosis psychotic disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>post-traumatic stress disorder</keyword>
	<keyword>sv2a</keyword>
	<keyword>ketamine</keyword>
	<keyword>PET</keyword>
</DOC>